-+ 0.00%
-+ 0.00%
-+ 0.00%

COGENT BIOSCIENCES ANNOUNCES BREAKTHROUGH THERAPY DESIGNATION FOR BEZUCLASTINIB IN COMBINATION WITH SUNITINIB FOR PATIENTS WITH GASTROINTESTINAL STROMAL TUMORS (GIST)

Reuters·01/26/2026 13:00:02

Please log in to view news